Evidence map›Paper›PMID 36825156›Full record

ReviewFrontiers in pharmacology2023

Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases.

Hongrui Wang, Yingying Su, Duoduo Chen, Qi Li, Shuyou Shi, Xin Huang, Mingli Fang, Ming Yang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hongrui WangDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Yingying SuDepartment of Anatomy, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Duoduo ChenDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Qi LiDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Shuyou ShiDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Xin HuangDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Mingli FangDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Ming YangDepartment of Molecular Biology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Jilin Medical University · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitory oligodeoxynucleotides (ODNs) are short single-stranded DNA, which capable of folding into complex structures, enabling them to bind to a large variety of targets. With appropriate modifications, the inhibitory oligodeoxynucleotides exhibited many features of long half-life time, simple production, low toxicity and immunogenicity. In recent years, inhibitory oligodeoxynucleotides have received considerable attention for their potential therapeutic applications in immune-mediated inflammatory diseases (IMIDs). Inhibitory oligodeoxynucleotides could be divided into three categories according to its mechanisms and targets, including antisense ODNs (AS-ODNs), DNA aptamers and immunosuppressive ODNs (iSup ODNs). As a synthetic tool with immunomodulatory activity, it can target RNAs or proteins in a specific way, resulting in the reduction, increase or recovery of protein expression, and then regulate the state of immune activation. More importantly, inhibitory oligodeoxynucleotides have been used to treat immune-mediated inflammatory diseases, including inflammatory disorders and autoimmune diseases. Several inhibitory oligodeoxynucleotide drugs have been developed and approved on the market already. These drugs vary in their chemical structures, action mechanisms and cellular targets, but all of them could be capable of inhibiting excessive inflammatory responses. This review summarized their chemical modifications, action mechanisms and applications of the three kinds of inhibitory oligodeoxynucleotidesin the precise treatment of immune-mediated inflammatory diseases.

Indexed as

antisense oligodeoxynucleotidesaptamerimmune responsesimmunosuppressive oligodeoxynucleotideinflammatory diseasesinhibitory oligodeoxynucleotides

Identifiers

PMID36825156
PMCPMC9941346
OpenAlexW4319443872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.